Supplement Documents for Results FY2013

Astellas Pharma Inc.

- **Financial Results of FY2013**
  - **J-GAAP**
  - **IFRS**

    *** The Company has adopted IFRS, effective from the fiscal year ended March 31, 2014**
- **Pipeline list**

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

<J-GAAP>

1. Consolidated Results

Fiscal Year: From April through March

J-GAAP

billion yen

	FY12 Full Year	FY13 Full Year	Change	Change (%)	billion yen FY13 Revised Forecasts
Net Sales	1,005.6	1,164.5	158.9	15.8%	1,155.0
Cost of Sales	324.1	345.6	21.5	6.6%	
Ratio to Net Sales	32.2%	29.7%			
Gross Profit	681.5	818.9	137.4	20.2%	
SG&A	527.6	641.6	114.0	21.6%	
Ratio to Net Sales	52.5%	55.1%			
Research and Development	182.0	214.6	32.7	18.0%	212.0
SG&A excluding R&D	345.7	427.0	81.3	23.5%	
Advertising and Sales Promotion	86.5	114.9	28.4	32.9%	
Personnel expenses	139.7	162.9	23.2	16.6%	
Other	119.5	149.1	29.7	24.8%	
Operating Income	153.9	177.3	23.4	15.2%	170.0
Ratio to Net Sales	15.3%	15.2%			14.7%
Non-Operating Income	4.1	2.4	-1.6	-40.0%	
Exchange Gain	1.5	-	-1.5	-	
Non-Operating Expenses	0.8	8.9	8.1	-	
Exchange Loss	-	8.1	8.1	-	
Ordinary Income	157.2	170.8	13.6	8.7%	170.0
Ratio to Net Sales	15.6%	14.7%			14.7%
Special Gains	5.8	15.4	9.5	164.2%	
Gain on sales of fixed assets	0.3	5.7	5.5	-	
Gain on sales of investment securities	5.4	5.0	-0.4	-7.0%	
Gain on sales of investments in subsidiaries	-	4.5	4.5	-	
Special Losses	38.3	54.4	16.1	42.1%	
Loss on sale and disposal of fixed assets	0.7	4.2	3.5	476.5%	
Loss on impairment of fixed assets	34.8	36.1	1.3	3.6%	
Restructuring costs	-	10.2	10.2	-	
Income before Income Taxes	124.7	131.7	7.1	5.7%	
Income Taxes	41.8	39.3	-2.5	-6.1%	
Net Income	82.9	92.4	9.6	11.6%	95.0
Ratio to Net Sales	8.2%	7.9%			8.2%
Comprehensive income	152.8	179.4	26.6	17.4%	

J-GAAP

2. Segment Information by Region

billion yen

		FY12 Full Year	FY13 Full Year	Change	Change (%)	FY13 Revised Forecasts
Net Sales		1005.6	1,164.5	158.9	15.8%	1,155.0
	Japan	557.5	550.7	-6.9	-1.2%	556.8
	Ratio to Net Sales	55.4%	47.3%			48.2%
	Americas	208.7	288.5	79.8	38.2%	280.4
	Ratio to Net Sales	20.8%	24.8%			24.3%
	Europe	196.5	267.4	71.0	36.1%	260.8
	Ratio to Net Sales	19.5%	23.0%			22.6%
	Asia and Oceania	42.9	58.0	15.0	35.0%	57.0
	Ratio to Net Sales	4.3%	5.0%			4.9%
Operating Income		153.9	177.3	23.4	15.2%	170.0
	Japan	83.7	64.7	-19.0	-22.7%	
	Ratio to Net Sales	54.4%	36.5%			
	Americas	23.3	39.7	16.4	70.2%	
	Ratio to Net Sales	15.1%	22.4%			
	Europe	51.5	83.3	31.7	61.6%	
	Ratio to Net Sales	33.5%	47.0%			
	Asia and Oceania	2.4	5.1	2.7	112.1%	
	Ratio to Net Sales	1.6%	2.9%			
	Eliminations	-7.1	-15.4	-8.3		

- Calculated according to locations of sellers.
- Europe: Including Middle and Near East and Africa

3. Overseas Sales

billion yen

		FY12 Full Year	FY13 Full Year	Change	Change (%)
Overseas Sales		464.0	622.4	158.4	34.1%
	Ratio to Net Sales	46.1%	53.4%		
	Americas	215.6	285.9	70.3	32.6%
	Ratio to Net Sales	21.4%	24.6%		
	Europe	188.8	255.8	67.0	35.5%
	Ratio to Net Sales	18.8%	22.0%		
	Asia and others	59.7	80.6	21.0	35.1%
	Ratio to Net Sales	5.9%	6.9%		

- Calculated according to locations of buyers.

J-GAAP

4. Exchange Rate

	FY12 Ave.	FY13 Ave.	FY12 End	FY13 End	FY13 Revised Forecasts
	yen				yen
Yen/USD	83	100	94	103	99
Yen/EUR	107	134	121	142	130

∗ Exchange rate fluctuations had positive impact by 113.9 billion yen on net sales and positive impact by 24.6 billion yen on operating income in FY2013

5. Per Share Information

	FY12 Full Year	FY13 Full Year	FY13 Revised Forecasts
			yen
The number of shares issued (thousand)	467,964	456,964	
Treasury Shares (thousand)	16,788	10,736	
The number of shares issued after deducting Treasury Stock (thousand)	451,176	446,228	
Earnings per share (Yen)	180.40	205.73	211.44
Dividend per share (Yen)	130	135	135
Return on Equity (%)	8.0%	8.4%	
Dividend on Equity (%)	5.7%	5.5%	

6. Research and Development Expenses

	FY12 Full Year	FY13 Full Year	Change	Change (%)	FY13 Revised Forecasts
		billion yen			billion yen
Research and Development	182.0	214.6	32.7	18.0%	212.0
Ratio to Net Sales	18.1%	18.4%			18.4%

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation

	FY12 Full Year	FY13 Full Year	Change	Change (%)	FY13 Revised Forecasts
		billion yen			billion yen
Addition to Property, Plant and Equipment					
Consolidated	32.1	27.4	-4.6	-14.5%	29.0
Depreciation(Tangible)					
Consolidated	17.7	22.8	5.1	29.0%	22.0
Amortisation(Intangible)					
Consolidated	29.8	38.9	9.2	30.7%	38.0
Amortization of Goodwill	10.3	5.9			5.9
Agensys	5.4	-			-
OSI	4.9	5.9			5.9

8. Sales of major products

J-GAAP

1)Sales of global products

billion yen

billion yen

	FY12 Full Year	FY13 Full Year	Change	Change (%)	FY13 Revised Forecasts
Prograf	161.8	181.4	19.6	12.1%	177.9
Sales by Astellas	157.3	176.2	18.9	12.0%	173.5
Japan (Including Graceptor)	49.4	50.4	1.0	2.0%	50.9
Americas	31.5	29.6	-1.8	-5.8%	28.9
Europe	57.5	71.2	13.7	23.8%	68.9
Advagraf	18.0	24.3	6.3	35.0%	
Asia and Oceania	18.9	25.0	6.1	32.1%	24.8
Exports to third parties	4.4	5.2	0.8	17.4%	4.4
Harnal	54.0	59.6	5.6	10.3%	59.7
Sales by Astellas	50.1	55.3	5.2	10.3%	55.0
Japan	23.0	20.2	-2.7	-11.9%	20.9
Europe	15.4	19.4	4.0	26.1%	18.6
Asia and Oceania	10.9	14.9	4.0	37.1%	14.7
Bulk and Royalties	3.9	4.3	0.4	10.4%	4.8
Vesicare	110.0	135.7	25.8	23.4%	130.1
Japan	29.8	30.7	0.9	2.9%	30.4
Americas	46.8	58.1	11.3	24.2%	54.8
Europe	30.1	42.7	12.5	41.7%	40.2
Asia and Oceania	3.0	3.8	0.9	29.8%	4.2
Betanis/Myrbetriq/BETMIGA	6.9	28.2	21.2	305.9%	26.0
Japan	5.3	11.6	6.3	118.4%	11.1
Americas	1.6	14.5	12.9	789.2%	13.1
Europe	0.0	2.1	2.1	-	1.8
Funguard/Mycamine	30.7	36.2	5.5	18.0%	36.2
Japan	12.9	12.3	-0.6	-4.5%	12.8
Americas	9.5	11.7	2.3	23.7%	11.0
Europe	6.0	8.8	2.8	47.3%	9.1
Asia and Oceania	2.3	3.4	1.0	44.6%	3.2
Protopic	17.9	25.0	7.1	39.9%	23.8
Japan	3.5	3.5	0.0	1.0%	3.6
Americas	7.9	11.7	3.8	47.5%	11.0
Europe	4.6	7.1	2.4	52.8%	6.4
Asia and Oceania	1.7	2.6	0.9	49.3%	2.7
XTANDI	12.2	54.6	42.4	346.8%	
US	12.2	44.3	32.0	262.6%	39.8
ex-US	0.0	10.4	10.4	-	
Americas (ex-US)	-	0.8	0.8	-	
Europe	0.0	9.5	9.5	-	
Asia and Oceania	-	0.0	0.0	-	
Eligard	15.0	18.7	3.7	24.9%	
Europe	15.0	18.7	3.7	24.7%	19.2
Asia and Oceania	-	0.0	0.0	-	

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle and Near East and Africa

J-GAAP

2)Sales of products in Japan

billion yen

<Global products>	FY12 Full Year	FY13 Full Year	Change	Change (%)	billion yen FY13 Revised Forecasts
Prograf（Including Graceptor）	49.4	50.4	1.0	2.0%	50.9
Harnal	23.0	20.2	-2.7	-11.9%	20.9
Vesicare	29.8	30.7	0.9	2.9%	30.4
Betanis	5.3	11.6	6.3	118.4%	11.1
Funguard	12.9	12.3	-0.6	-4.5%	12.8
Protopic	3.5	3.5	0.0	1.0%	3.6
<Domestic products>					
Lipitor [Family]	70.6	62.4	-8.2	-11.6%	63.0
Caduet	9.6	10.7	1.0	10.7%	
Micardis [Family]	89.6	97.6	7.9	8.9%	98.0
Micombi	11.6	11.8	0.2	2.1%	
Micamlo	15.7	21.4	5.8	36.8%	
Gaster	30.2	25.7	-4.5	-14.9%	26.7
Myslee	32.2	28.2	-4.0	-12.6%	27.4
Seroquel	28.5	19.6	-8.9	-31.2%	19.7
Vaccines	28.8	35.0	6.2	21.4%	34.1
Cefzon	7.2	6.4	-0.8	-11.1%	6.4
Frandol	8.7	8.0	-0.6	-7.3%	8.1
Celecox	37.4	44.3	6.9	18.4%	44.8
Geninax	12.3	11.7	-0.6	-4.5%	13.8
Bonoteo	10.7	14.1	3.5	32.4%	14.1
Symbicort	27.7	35.6	7.9	28.5%	35.7
Argamate	6.1	6.1	-0.0	-0.5%	6.3
Kiklin	0.6	1.4	0.9	160.0%	1.4
Gonax	0.7	2.5	1.9	289.0%	3.0
Cimzia	0.1	3.2	3.1	-	4.6
Total Rx Sales In Japan	535.8	535.6	-0.1	-0.0%	540.5

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

billion yen

	FY12 Full Year	FY13 Full Year	Change	Change (%)	billion yen FY13 Revised Forecasts
Scan* (Americas)	53.1	61.8	8.7	16.5%	59.1
Lexiscan	47.6	58.6	11.1	23.3%	
AmBisome (Americas)	6.3	8.1	1.7	27.6%	7.4
Tarceva	36.6	44.7	8.2	22.3%	
(US)	23.6	28.9	5.2	22.1%	
(ex-US)	12.9	15.9	2.9	22.7%	
Qutenza (Europe)	0.9	1.4	0.5	59.8%	
Dificlir (Europe)		1.3			

* Adenoscan + Lexiscan

J-GAAP

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY12 Full Year	FY13 Full Year	Change	Change (%)	Unit:M$ FY13 Revised Forecasts
Net Sales	2,512	2,878	366	14.6%	2,820
Prograf	379	296	-83	-21.9%	291
Scan*	639	617	-22	-3.5%	594
Lexiscan	572	585	13	2.2%	
AmBisome	76	80	4	5.7%	74
Protopic	95	116	21	22.3%	111
VESIcare	563	580	17	2.9%	551
Myrbetriq	20	145	125	-	132
Mycamine	114	117	3	2.6%	111
Tarceva	440	446	6	1.4%	
US	284	288	4	1.2%	
ex-US	156	158	3	1.7%	
XTANDI	147	450	303	206.3%	
US	147	441	295	200.6%	400
Americas (ex-US)	-	8	8	-	

* Adenoscan + Lexiscan

Unit:M€

Europe	FY12 Full Year	FY13 Full Year	Change	Change (%)	Unit:M€ FY13 Revised Forecasts
Net Sales	1,834	1,990	156	8.5%	2,006
Harnal	181	177	-4	-2.0%	180
Sales by Astellas	144	145	0	0.5%	143
Capsule	64	69	5	8.1%	71
OCAS	80	76	-4	-5.5%	72
Bulk and Royalties	37	32	-4	-11.9%	37
Prograf	577	568	-9	-1.6%	563
Sales by Astellas	537	530	-7	-1.3%	530
Advagraf	168	181	13	7.6%	
Exports to third parties	40	38	-2	-5.4%	33
Vesicare	281	317	36	13.0%	309
BETMIGA	0	15	15	-	14
Protopic	43	53	9	21.8%	49
Mycamine	56	65	10	17.5%	70
Eligard	140	139	-0	-0.5%	148
Qutenza	8	11	2	27.4%	
Dificlir		10			
XTANDI	0	71	70	-	

- Europe: Including Middle and Near East and Africa

9.Consolidated Balance Sheets

J-GAAP

Billion yen

	31-Mar-13 Amount	31-Mar-14 Amount	Change
Assets	**1,445.6**	**1,551.8**	**106.2**
Current assets	**827.2**	**971.1**	**143.9**
Cash on hand and in banks	233.8	286.3	52.5
Trade notes and accounts receivable	286.1	301.1	15.0
Marketable securities	78.9	138.8	59.9
Merchandise and finished goods	92.7	95.8	3.1
Work in process	13.3	15.6	2.3
Raw materials and supplies	22.2	24.0	1.8
Deferred tax assets	61.7	68.9	7.2
Other	40.4	42.3	1.9
Allowance for doubtful receivables	-1.9	-1.7	0.2
Fixed assets	**618.4**	**580.7**	**-37.7**
Property, plant and equipment	**218.5**	**199.6**	**-18.9**
Buildings and structures	116.8	118.4	1.6
Machinery, equipment and vehicles	28.9	35.9	7.0
Tools, furniture and fixtures	15.4	14.8	-0.6
Land	30.2	19.8	-10.4
Construction in progress	25.8	9.1	-16.7
Other	1.4	1.6	0.2
Intangible fixed assets	**294.8**	**252.9**	**-42.0**
Goodwill	96.0	98.0	2.0
Patents	138.1	112.4	-25.6
Other	60.8	42.4	-18.4
Investments and other assets	**105.1**	**128.3**	**23.2**
Investment securities	61.6	72.7	11.0
Deferred tax assets	27.1	31.8	4.7
Other	16.3	23.8	7.5
Allowance for doubtful receivables	-0.0	-0.0	0.0

J-GAAP

Billion yen

	31-Mar-13	31-Mar-14	
	Amount	Amount	Change
Liabilities and Net assets	**1,445.6**	**1,551.8**	**106.2**
Liabilities	**383.5**	**411.7**	**28.2**
Current liabilities	**313.5**	**328.0**	**14.5**
Trade notes and accounts payable	102.8	102.0	-0.8
Accrued expenses	94.4	119.2	24.8
Accrued bonus for directors	0.1	0.1	0.0
Allowance for sales rebates	4.4	4.5	0.1
Other	111.9	102.2	-9.7
Long-term liabilities	**70.0**	**83.7**	**13.7**
Deferred tax liabilities	34.7	30.6	-4.1
Accrued retirement benefits for employees	18.3	-	-18.3
Net defined benefit liability	-	38.5	38.5
Other	17.0	14.6	-2.4
Net assets	**1,062.0**	**1,140.1**	**78.0**
Common stock	103.0	103.0	-
Capital surplus	176.8	176.8	-
Retained earnings	917.5	903.8	-13.7
Treasury stock	-72.3	-54.5	17.8
Unrealized holding gains on securities	16.0	23.8	7.9
Foreign currency translation adjustments	-80.9	-1.8	79.1
Remeasurements of defined benefit plans	-	-13.1	-13.1
Stock subscription rights	1.9	2.1	0.2

<IFRS>

1. Consolidated Results (Full Basis (Non-adjustment))

IFRS

Fiscal Year: From April through March

billion yen

	FY12 Full Year	FY13 Full Year	Change	Change (%)
Sales	981.9	1,139.9	158.0	16.1%
Cost of sales	308.7	330.6	21.9	7.1%
Ratio to Sales	31.4%	29.0%		
Gross profit	673.2	809.3	136.1	20.2%
SG&A expenses	318.9	397.0	78.1	24.5%
Ratio to Sales	32.5%	34.8%		
Advertising and sales promotion	87.3	112.1	24.8	28.4%
Personnel expenses	140.0	167.8	27.8	19.9%
Other	91.6	117.0	25.5	27.8%
R&D expenses	159.1	191.5	32.4	20.3%
Ratio to Sales	16.2%	16.8%		
Amortisation of intangible assets	28.3	36.0	7.7	27.4%
Share of profits of associates and joint ventures	1.1	1.5	0.3	27.5%
Other income	2.9	11.6	8.7	304.7%
Gain on sales of property, plant and equipment	0.3	5.5	5.3	-
Gain on sales of subsidiaries	-	4.7	4.7	-
Net foreign exchange gains	1.5	-	-1.5	-
Other expense	49.3	81.0	31.7	64.4%
Loss on sales and disposal of property, plant and equipment	0.6	4.1	3.5	604.5%
Impairment losses	44.6	55.8	11.2	25.1%
Restructuring costs	-	10.1	10.1	-
Net foreign exchange losses	-	8.0	8.0	-
Operating profit	121.6	116.8	-4.8	-3.9%
Ratio to Sales	12.4%	10.2%		
Finance income	7.3	6.8	-0.5	-7.0%
Gain on sales of available-for-sale financial assets	5.4	5.0	-0.4	-7.0%
Finance expense	1.8	1.7	-0.2	-8.7%
Impairment losses for available-for-sale financial assets	1.1	1.2	0.1	9.1%
Profit before tax	127.1	122.0	-5.1	-4.0%
Ratio to Sales	12.9%	10.7%		
Income tax expense	34.7	31.1	-3.6	-10.2%
Profit for the year	92.5	90.9	-1.6	-1.7%
Ratio to Sales	9.4%	8.0%		
Comprehensive income	158.3	182.1	23.8	15.0%

IFRS

2. Consolidated Results (Core Basis)

billion yen

	FY12 Full Year	FY13 Full Year	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Sales	981.9	1,139.9	158.0	16.1%	1,192.0	4.6%
Cost of sales	308.7	330.6	21.9	7.1%		
Ratio to Sales	31.4%	29.0%				
Gross profit	673.2	809.3	136.1	20.2%		
SG&A expenses	318.9	397.0	78.1	24.5%		
Ratio to Sales	32.5%	34.8%				
Advertising and sales promotion	87.3	112.1	24.8	28.4%		
Personnel expenses	140.0	167.8	27.8	19.9%		
Other	91.6	117.0	25.5	27.8%		
R&D expenses	159.1	191.5	32.4	20.3%	198.0	3.4%
Ratio to Sales	16.2%	16.8%			16.6%	
Amortisation of intangible assets	28.3	36.0	7.7	27.4%		
Share of profits of associates and joint ventures	1.1	1.5	0.3	27.5%		
Operating profit	168.0	186.3	18.2	10.9%	208.0	11.7%
Ratio to Sales	17.1%	16.3%			17.4%	
Finance income	1.9	1.6	-0.3	-14.0%		
Finance expense	0.4	0.4	0.0	4.3%		
Profit before tax	169.5	187.5	17.9	10.6%		
Ratio to Sales	17.3%	16.4%				
Income tax expense	50.7	54.7	3.9	7.8%		
Profit for the year	118.8	132.8	14.0	11.8%	154.0	16.0%
Ratio to Sales	12.1%	11.6%			12.9%	

3. Exchange Rate

yen

	FY12 Ave.	FY13 Ave.	FY12 End	FY13 End	Forecasts FY14 Full Year
Yen/USD	83	100	94	103	100
Yen/EUR	107	134	121	142	140

∗ Exchange rate fluctuations had positive impact by 113.0 billion yen on sales and positive impact by 24.2 billion yen on Core operating profit in FY2013.

4. Reconciliation of Full Basis (Non-Adjustment) to Core Basis

Fiscal Year: From April through March

IFRS

Billion yen

Account item	FY2012			FY2013		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**981.9**	**-**	**981.9**	**1,139.9**	**-**	**1,139.9**
Cost of sales	308.7	-	308.7	330.6	-	330.6
Gross profit	**673.2**	**-**	**673.2**	**809.3**	**-**	**809.3**
SG&A expenses	318.9	-	318.9	397.0	-	397.0
R&D expenses	159.1	-	159.1	191.5	-	191.5
Amortisation of intangible assets	28.3	-	28.3	36.0	-	36.0
Share of profits of associates and joint ventures	1.1	-	1.1	1.5	-	1.5
Other income *1	2.9	-2.9	-	11.6	-11.6	-
Other expense *1	49.3	-49.3	-	81.0	-81.0	-
Operating profit	**121.6**	**46.4**	**168.0**	**116.8**	**69.4**	**186.3**
Finance income *2	7.3	-5.4	1.9	6.8	-5.2	1.6
Finance expense *2	1.8	-1.4	0.4	1.7	-1.2	0.4
Profit before tax	**127.1**	**42.4**	**169.5**	**122.0**	**65.5**	**187.5**
Income tax expense	34.7	16.1	50.7	31.1	23.6	54.7
Profit for the year	**92.5**	**26.3**	**118.8**	**90.9**	**41.9**	**132.8**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for property, plant and equipment and intangible assets, gain/loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Comparison between IFRS (Full Basis (Non-Adjustment)) and J-GAAP in FY2013 PL

IFRS

Fiscal Year: From April through March

billion yen

J-GAAP	FY13 J-GAAP	FY13 IFRS	Diff.	IFRS	Major factors for differences
Net sales	**1,164.5**	**1,139.9**	**-24.6**	**Sales**	Agent transactions are presented at net value (offset against COGS)
Cost of sales	345.6	330.6	-15.0	Cost of sales	Agent transactions Royalty expenses reclassified from SG&A to COGS
Gross profit	**818.9**	**809.3**	**-9.6**	**Gross profit**	
R&D expenses	214.6	191.5	-23.2	R&D expenses	Capitalization of upfront / milestone payments for R&D pipelines, etc. Reclassification of certain PMS cost to SG&A
SG&A excluding R&D expenses	427.0	397.0	-30.0	SG&A expenses	Discontinuation of goodwill amortisation Reclassification of amortisation of intangible assets to SG&A Reclassification of certain PMS cost from R&D
—		36.0	36.0	Amortisation of intangible assets	Reclassification from SG&A
—		1.5	1.5	Share of profits of associates and joint ventures	
—		11.6	11.6	Other income	Mainly reclassification from special gains: gain on sales of PP&E, gain on sales of subsidiaries, etc.
—		81.0	81.0	Other expense	Mainly reclassification from special losses: impairment losses, restructuring cost, etc. Additinal impairment of capitalized in-license R&D payment under IFRS.
Operating income	**177.3**	**116.8**	**-60.5**	**Operating profit**	
Non-Operating income	2.4		-2.4	—	
Non-Operating expenses	8.9		-8.9	—	
Ordinary income	170.8		-170.8	—	
Special gains	15.4		-15.4	—	
Special losses	54.4		-54.4	—	
—		6.8	6.8	Finance income	Gain on sales of available-for-sale financail assets, interest income, dividend income
—		1.7	1.7	Finance expense	Impairment losses of available-for-sale financial assets, other finance expense
Income before income taxes	131.7	122.0	-9.7	**Profit before tax**	
Income taxes	39.3	31.1	-8.2	Income tax expense	Tax effect due to the elmination of unrealised gain/loss Tax effect due to other IFRS adjustments
Net income	**92.4**	**90.9**	**-1.6**	**Profit for the year**	

IFRS

6. Segment Information by Region

billion yen

		FY12 Full Year	FY13 Full Year	Change	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Sales		981.9	1,139.9	158.0	16.1%	1,192.0	4.6%
	Japan	536.5	530.6	-5.9	-1.1%	528.4	-0.4%
	Ratio to Sales	54.6%	46.5%			44.3%	
	Americas	207.6	287.0	79.4	38.3%	289.2	0.8%
	Ratio to Sales	21.1%	25.2%			24.3%	
	Europe	194.9	264.3	69.4	35.6%	305.6	15.6%
	Ratio to Sales	19.8%	23.2%			25.6%	
	Asia and Oceania	42.9	58.0	15.0	35.0%	68.7	18.6%
	Ratio to Sales	4.4%	5.1%			5.8%	

- Calculated according to locations of sellers.
- Europe: Including Middle and Near East and Africa.

7. Per Share Information

	FY12 Full Year	FY13 Full Year	Forecasts FY14 Full Year
The number of shares issued (thousand) *	2,339,823	2,284,823	
Treasury Shares (thousand) *	83,942	53,681	
The number of shares issued after deducting Treasury Stock (thousand) *	2,255,880	2,231,141	
Earnings per share (Yen) *	40.27	40.45	
Earnings per share (Yen) * Core Basis	51.73	59.11	69.02
Dividend per share (Yen) **	130	135	29
Return on Equity (%)	8.0%	7.4%	
Dividend on Equity (%)	5.2%	5.0%	

* The Company conducted a 5-for-1 stock split of common stock on April 1, 2014.
These figures are calculated on the assumption that the above stock split was implemented at the beginning of FY2012.
** Dividend per share for FY2012 & FY2013 is listed before stock split.

8. Addition to Property, Plant and Equipment

Depreciation/Amortisation

billion yen

		FY12 Full Year	FY13 Full Year	Change -	Change (%)	Forecasts FY14 Full Year	Change from FY13 Change (%)
Addition to Property, Plant and Equipment							
	Consolidated	32.1	27.3	-4.8	-14.9%	33.0	20.9%
Depreciation(Tangible)							
	Consolidated	18.6	23.2	4.6	24.7%	23.0	-0.8%
Amortisation(Intangible) *							
	Consolidated	32.6	41.1	8.5	26.2%	42.0	2.1%

* Amortisation(Intangible): Including amortisation of software, etc.

9. Sales of major products

IFRS

1)Sales of global products

billion yen

	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf	181.1	181.3	0.1%
Sales by Astellas	175.9	177.6	1.0%
Japan (Including Graceptor)	50.4	49.6	-1.5%
Americas	29.6	27.4	-7.5%
Europe	70.8	71.4	0.8%
Advagraf	24.0		
Asia and Oceania	25.0	29.2	16.9%
Exports to third parties	5.2	3.7	-29.2%
Harnal	59.5	55.9	-6.0%
Sales by Astellas	55.2	52.0	-5.8%
Japan	20.2	16.0	-20.9%
Europe	19.4	18.7	-3.6%
Asia and Oceania	14.9	16.8	12.3%
Bulk and Royalties	4.3	4.0	-7.9%
Vesicare	133.8	120.7	-9.8%
Japan	30.7	24.2	-21.1%
Americas	58.1	48.2	-17.0%
Europe	40.8	42.9	5.3%
Asia and Oceania	3.8	4.8	26.3%
Betanis/Myrbetriq/BETMIGA	28.2	56.4	100.0%
Japan	11.6	20.9	80.3%
Americas	14.5	25.9	78.3%
Europe	2.1	9.3	349.5%
Funguard/Mycamine	36.1	36.8	2.0%
Japan	12.3	11.4	-7.2%
Americas	11.7	10.9	-7.6%
Europe	8.6	10.1	17.6%
Asia and Oceania	3.4	4.4	29.2%
Protopic	25.0	19.7	-21.3%
Japan	3.5	-	-
Americas	11.7	8.4	-27.6%
Europe	7.1	7.4	5.4%
Asia and Oceania	2.6	3.6	39.5%
XTANDI	54.6		
US	44.3	56.0	26.5%
ex-US	10.3		
Americas (ex-US)	0.8		
Europe	9.5	26.6	181.4%
Asia and Oceania	0.0		
Eligard	18.3		
Europe	18.3	20.9	14.1%
Asia and Oceania	0.0		

- Sales of products in Japan are shown in a gross sales basis.
- Europe: Including Middle and Near East and Africa

IFRS

2)Sales of products in Japan

billion yen

<Global products>	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Prograf （Including Graceptor）	50.4	49.6	-1.5%
Harnal	20.2	16.0	-20.9%
Vesicare	30.7	24.2	-21.1%
Betanis	11.6	20.9	80.3%
Funguard	12.3	11.4	-7.2%
Protopic	3.5	-	-
<Domestic products>			
Lipitor [Family]	62.4	52.6	-15.7%
Caduet	10.7		
Micardis [Family]	97.6	97.5	-0.1%
Micombi	11.8		
Micamlo	21.4		
Gaster	25.7	19.5	-24.2%
Myslee	28.2	20.2	-28.5%
Seroquel	19.6	12.6	-35.6%
Vaccines	35.0	35.7	2.2%
Cefzon	6.4	5.3	-16.9%
Celecox	44.3	45.9	3.6%
Geninax	11.7	12.4	5.1%
Bonoteo	14.1	14.7	4.0%
Symbicort	35.6	36.3	1.9%
Argamate	6.1	6.4	5.6%
Kiklin	1.4	2.1	44.5%
Gonax	2.5	4.8	90.0%
Cimzia	3.2	12.3	279.4%
Total Rx Sales In Japan	515.6	508.3	-1.4%

- Sales of products in Japan are shown in a gross sales basis.

3)Sales of products in Americas and Europe

billion yen

		FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Scan*	(Americas)	61.8	53.3	-13.8%
Lexiscan		58.6		
AmBisome	(Americas)	8.1	8.0	-1.0%
Tarceva		44.7		
	(US)	28.9		
	(ex-US)	15.9		
Qutenza	(Europe)	1.4		
Dificlir	(Europe)	1.3		

* Adenoscan + Lexiscan

IFRS

4)Sales in Americas and Europe(Local currency)

Unit:M$

Americas	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	2,863	2,892	1.0%
Prograf	296	274	-7.3%
Scan*	617	533	-13.6%
Lexiscan	585		
AmBisome	80	80	-0.8%
Protopic	116	84	-27.4%
VESIcare	580	482	-16.8%
Myrbetriq	145	259	78.8%
Mycamine	117	109	-7.4%
Tarceva	446		
US	288		
ex-US	158		
XTANDI	450		
US	441	560	26.8%
Americas (ex-US)	8		

* Adenoscan + Lexiscan

Unit:M€

Europe	FY13 Full Year	Forecasts FY14 Full Year	Change from FY13 Change (%)
Net Sales	1,967	2,183	11.0%
Harnal	176	162	-8.3%
Sales by Astellas	144	133	-7.5%
Capsule	69	66	-3.4%
OCAS	75	67	-11.3%
Bulk and Royalties	32	29	-11.6%
Prograf	565	536	-5.1%
Sales by Astellas	527	510	-3.3%
Advagraf	179		
Exports to third parties	38	26	-31.1%
Vesicare	303	307	1.1%
BETMIGA	15	66	331.4%
Protopic	52	53	1.2%
Mycamine	64	72	12.8%
Eligard	136	149	9.6%
Qutenza	11		
Dificlir	9		
XTANDI	70	190	170.0%

- Europe: Including Middle and Near East and Africa

10.Consolidated statements of financial position

IFRS

Billion yen

			1-Apr-12	31-Mar-13	31-Mar-14	
			Amount	Amount	Amount	Change
Assets			**1,511.1**	**1,565.3**	**1,653.1**	**87.8**
	Non-current assets		**794.7**	**792.6**	**739.8**	**-52.7**
		Property, plant and equipment	192.9	211.1	191.5	-19.7
		Goodwill	94.2	107.6	116.8	9.1
		Other intangible assets	367.2	340.6	280.1	-60.5
		Investments in associates and joint ventures	0.8	1.2	1.8	0.6
		Deferred tax assets	57.4	45.2	45.5	0.4
		Other financial assets	76.7	81.1	95.0	13.9
		Other non-current assets	5.5	5.7	9.2	3.5
	Current assets		**716.4**	**772.7**	**913.3**	**140.6**
		Inventories	112.7	127.1	135.2	8.1
		Trade and other receivables	288.3	308.2	332.6	24.4
		Income tax receivable	6.6	10.5	2.7	-7.8
		Other financial assets	48.8	50.9	35.4	-15.5
		Other current assets	6.1	9.4	12.1	2.6
		Cash and cash equivalents	252.4	264.9	391.4	126.5
		Assets held for sale	1.5	1.6	3.9	2.2

IFRS

Billion yen

	1-Apr-12	31-Mar-13	31-Mar-14	
	Amount	Amount	Amount	Change
Equity and Liabilities	**1,511.1**	**1,565.3**	**1,653.1**	**87.8**
Equity	**1,125.2**	**1,174.6**	**1,268.5**	**93.9**
Equity attributable to owners of the parent	**1,125.2**	**1,174.6**	**1,268.5**	**93.9**
Share capital	103.0	103.0	103.0	-
Capital surplus	176.8	176.8	176.8	-
Treasury shares	-23.1	-72.3	-54.5	17.8
Retained earnings	848.1	875.5	864.8	-10.6
Other components of equity	20.3	91.6	178.4	86.8
Liabilities	**385.9**	**390.7**	**384.6**	**-6.0**
Non-current liabilities	**64.0**	**65.8**	**43.9**	**-21.8**
Trade and other payables	11.6	4.9	0.1	-4.8
Deferred tax liabilities	17.5	15.3	0.0	-15.3
Retirement benefit liabilities	24.8	32.2	27.2	-5.0
Provisions	1.7	1.9	4.3	2.4
Other financial liabilities	1.5	1.4	0.7	-0.6
Other non-current liabilities	6.7	10.1	11.7	1.5
Current liabilities	**321.9**	**324.9**	**340.7**	**15.8**
Trade and other payables	199.3	201.8	187.0	-14.7
Income tax payable	24.4	10.4	13.2	2.9
Provisions	32.4	48.1	66.4	18.3
Other financial liabilities	1.1	1.4	1.1	-0.3
Other current liabilities	64.7	63.3	73.0	9.6

11. Employee

Number of employees

	FY12 End	FY13 End
Total	17,454	17,649
Japan	8,153	8,082
Americas	2,980	2,883
Europe	4,356	4,580
Asia and Oceania	1,965	2,104
Total Medical Representatives	6,350	6,340

- Europe: Including Middle and Near East and Africa

12. Shareholders

	FY12 End	FY13 End
Banks	30.1%	29.2%
Securities	4.3%	4.4%
Other companies	3.8%	3.3%
Foreign companies	49.8%	53.4%
Individuals and others	8.5%	7.3%
Treasury shares	3.6%	2.3%

<Pipeline list>

R&D Pipeline (May 2014)

1. Global Development

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin*	Remarks
MDV3100 enzalutamide	XTANDI (Mar. 2014)	Androgen receptor inhibitor	Castration-resistant prostate cancer**	Japan	Oral	Medivation	

*"In-house" shown in the "origin" column includes discovery by collaborative research. (The same applicable hereafter.)

**Precautions regarding indication include the description that the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

(2) Filed

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in patients who have not received chemotherapy	US Filed (Mar. 2014) Europe Filed (Apr. 2014) Japan Phase-III Asia Phase-III	Oral	Medivation	New indication
		Non-Metastatic castration-resistant prostate cancer	US Phase-III Europe Phase-III Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication

(3) Phase-lll / Phase-ll (1/2)

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
erlotinib	HER1/EGFR tyrosine kinase inhibitor	Pediatric ependymoma	US Phase-III	Oral	In-house (co-development with Roche/Genentech)	Not a new indication, rather a supplement whose results are planned to submit to the FDA
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	Europe/US/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Cubist	

(3) Phase-lll / Phase-ll (2/2)

Stage in the most advanced territory

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-II (US/Europe Phase-II*)	Oral	In-house	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP3652	Inhibition of afferent nerve activity	Bladder pain syndrome / Interstitial cystitis	Europe Phase-II Japan Phase-I	Oral	In-house	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP4901 (AKP-002)	PDE9 inhibitor	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Japan Phase-II	Oral	ASKA	
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	

*A license agreement was executed with Janssen Biotech, Inc. for the development and commercialization worldwide except for Japan.
Phase-IIb studies will be completed by Astellas.

2. Local Development: Japan

(1) Phase-lll / Phase-ll (1/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
YM060 ramosetron	5-HT3 receptor antagonist	Diarrhea-predominant irritable bowel syndrome Female patients	Japan Phase-III	Oral	In-house	New indication
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication
FK949E quetiapine	Serotonin/dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
certolizumab pegol	PEGylated anti-tumor necrosis factor-alpha antibody	Methotrexate-naive rheumatoid arthritis	Japan Phase-III	Injection	UCB	New indication
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Phase-III	Oral	Amgen	New indication
		Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral		New formulation
nateglinide	Fast acting insulin secretion enhancer	Type 2 diabetes Combination with DPP-4 inhibitors	Japan Phase-III	Oral	Ajinomoto	New indication

(1) Phase-lll / Phase-ll (2/2)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hyperlipidemia	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
AMG 102 rilotumumab	Anti-HGF monoclonal antibody	Gastric cancer	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Phase-III	Injection	UMN Pharma	
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome	Japan Phase-II	Oral	Ironwood	
ASP7991	Calcium-sensing receptor activator	Secondary hyperparathyroidism	Japan Phase-II	Oral	In-house	

3. Local Development: Europe

(1) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral diabetic neuropathy	Europe Phase-III	Patch	NeurogesX	New indication

4. Local Development: US

(1) Phase-lll / Phase-ll

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
isavuconazole	Azole antifungal	Invasive aspergillosis	US Phase-III	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US Phase-III			

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Origin
AGS-16M8F/ AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP9226	Neuropathic pain	Oral	In-house
ASP8232	Diabetic nephropathy	Oral	In-house
ASP3662	Alzheimer's disease	Oral	In-house
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP2215	Cancer	Oral	In-house
ASP3325	Hyperphosphatemia	Oral	In-house
CK-2127107	Skeletal muscle disease (non-neuromuscular indications)	Oral	Cytokinetics
ASP5878	Cancer	Oral	In-house
AMG 337	Gastric cancer	Oral	Amgen (co-development with Amgen Astellas)
ASP8273	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
ASP7657	Diabetic nephropathy	Oral	In-house
ASP3700	Osteoarthritis	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)

6. Project Discontinued

Code No. Generic Name	Area / Phase	Target Disease	Reason
ASP7487 (OSI-906) linsitinib	US Phase-II	Ovarian cancer	Discontinued the development, as the Phase-II study did not demonstrate the expected efficacy.
ASP0306	Phase-I	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Discontinued for strategic reasons.
ASP6432	Phase-I	Lower urinary tract symptoms associated with benign prostatic hyperplasia	Discontinued for strategic reasons.
ASP9853	Phase-I	Cancer	Discontinued for strategic reasons.

7. Deleted from the Pipeline List

Code No. Generic Name	Area / Phase	Target Disease	Reason
ASP4130 tivozanib	US/Europe Phase-II	Colorectal cancer, Breast cancer	Discontinued the Phase-II clinical trials for colorectal cancer and breast cancer. Excercised the right to terminate the license agreement for strategic reasons, based on the clinical status of the three indications studied (renal cell carcinoma, colorectal cancer, breast cancer). The termination will be effective August 11, 2014, at which time tivozanib right will be returned to AVEO.

<Changes from the Previous Announcement on February 3, 2014> (Changed underlined items)

Launched

-Midazolam: Removed the previous item below.

-Ipragliflozin: Removed the previous item below. It was launched in Japan in April 2014.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin	Remarks
midazolam	Dormicum (Dec. 2013)	Benzodiazepine sedative	Sedation during surgery and procedures for dental, oral and maxillofacial care	Japan	Injection	Roche	New indication
ASP1941 ipragliflozin	Suglat (Jan. 2014)	SGLT2 inhibitor	Type 2 diabetes	Japan	Oral	In-house (co-development with Kotobuki)	

Approved

-Enzalutamide: Approved in Japan in March 2014.

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	XTANDI (Mar. 2014)	Androgen receptor inhibitor	Castration-resistant prostate cancer*	Japan	Oral	Medivation	

*Precautions regarding indication include the description that the efficacy and safety of the drug have not been established in patients with prostate cancer who have not received chemotherapy.

Filed

-Enzalutamide: Filed in US/Europe for metatstatic castration-resistant prostate cancer in patients who have not received chemotherapy.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer in patients who have not received chemotherapy	US Filed (Mar. 2014) Europe Filed (Apr. 2014) Japan Phase-III Asia Phase-III	Oral	Medivation	New indication

Phase-III / Phase-II

-Erlotinib: Deleted non-small cell lung cancer (combination with MetMAb) from the target disease because Roche, who conducted the studies for it, terminated the studies.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
erlotinib	HER1/EGFR tyrosine kinase inhibitor	~~Non-small cell lung cancer (combination with MetMAb),~~ Pediatric ependymoma	US Phase-III	Oral	In-house (co-development with Roche/Genentech)	~~New indication~~ Not a new indication, rather a supplement whose results are planned to submit to the FDA

-Isavuconazole: Updated the development area and moved to the part of "Local Development: US" in accordance with the amended license agreement.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
isavuconazole	Azole antifungal	Invasive aspergillosis	US~~/Europe~~ Phase-III	Injection Oral	Basilea	
		Candidemia / Invasive candidiasis	US~~/Europe~~ Phase-III			

-ASP0113: Entered into Phase-III in the following target in Japan.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	

-Beraprost sodium: Changed the description of remarks.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
YM533 beraprost sodium	Prostacyclin receptor stimulator	Chronic renal failure (primary, nephrosclerosis)	Japan/Asia Phase-III	Oral	Toray	New indication ~~New formulation~~

-Bixalomer: Added the information on development of new formulation.

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Origin	Remarks
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral	Amgen	New formulation

Phase-I

-Mirabegron [Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients]: Entered into Phase-I.

-ASP7657 [Diabetic nephropathy]: Entered into Phase-I.

-ASP3700 [Osteoarthritis]: Entered into Phase-I.

-AGS67E [Cancer (ADC technology)]: Entered into Phase-I.

Project Discontinued

-Linsitinib [Ovarian cancer] in Phase-II: Discontinued the development.

-ASP0306 [Lower urinary tract symptoms associated with benign prostatic hyperplasia] in Phase-I: Discontinued the development.

-ASP6432 [Lower urinary tract symptoms associated with benign prostatic hyperplasia] in Phase-I: Discontinued the development.

-ASP9853 [Cancer] in Phase-I: Discontinued the development.

Deleted from the Pipeline List

-Tivozanib [Colorectal cancer, Breast cancer] in Phase-II: Deleted from the list because we excercised the right to terminate the license agreement for strategic reasons, based on the clinical status of the three indications studied. The termination will be effective August 11, 2014, at which time tivoazanib right will be returned to AVEO.